Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBITDA (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed EBITDA for 4 consecutive years, with -$28.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 41.98% to -$28.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$110.5 million through Dec 2025, down 20.82% year-over-year, with the annual reading at -$110.5 million for FY2025, 20.82% down from the prior year.
  • EBITDA hit -$28.3 million in Q4 2025 for Taysha Gene Therapies, up from -$34.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$16.2 million in Q4 2023 to a low of -$54.0 million in Q4 2022.
  • Historically, EBITDA has averaged -$27.3 million across 4 years, with a median of -$24.9 million in 2022.
  • Biggest five-year swings in EBITDA: surged 69.9% in 2023 and later crashed 59.37% in 2024.
  • Year by year, EBITDA stood at -$54.0 million in 2022, then surged by 69.9% to -$16.2 million in 2023, then decreased by 22.69% to -$19.9 million in 2024, then crashed by 41.98% to -$28.3 million in 2025.
  • Business Quant data shows EBITDA for TSHA at -$28.3 million in Q4 2025, -$34.0 million in Q3 2025, and -$26.8 million in Q2 2025.